Medical Device leader Abbott is working to expand their portfolio of neuromodulation technologies with the launch of the IonicRF Generator. This product will expand their leading medical device products and offer relief to customers with chronic pain.
Abbott has begun the launch of their first company-developed radiofrequency ablation system. This product can treat lower back pain, sacroiliac joint pain, and several discrete areas affecting the neck and spine. Studies have shown that radiofrequency ablation can treat areas that have failed to resolve through other treatments such as physical therapy or various forms for medication.
Keith Boettiger, Vice President of Abbott’s Neuromodulation Division said, “Most people who are candidates for radiofrequency ablation have tried other therapies, such as medications and injections, with limited success. As a result, they are now seeking an alternative solution that does not require surgery or the use of opioid medication.”
Studies have also shown that one treatment can relieve pain for six months to a year. Each individual’s pain is unique and through the use of IonicRF, the customer is provided with more treatment options to best suit their needs.
Abbott’s IonicRF Generator is designed to target specific nerves and burn them in order to prevent the nervous system from reporting pain to the brain. The product has recently gained approval by the FDA and is already launched in Europe. The system works with Abbott’s three-electrode radiofrequency probe, which targets peripheral nerves around the hip bones and is paired with their needles and electrodes to provide a minimally invasive experience. One of the most astounding features of the device is its ability to target four sites at once through independently controlled channels and real-time temperature monitoring.
Abbott currently meets healthcare needs in over 160 countries and has over 107,000 colleagues working with them. According to a report from Grand View Research, the global radiofrequency ablation device market value was $2.8 billion in 2016 and is expected to reach $6.7 billion by 2026. Abbott is launching the IonicRF in a time with an increasing elderly population and a preference for minimally invasive surgeries, which will benefit the company and its customers.
Abbott’s leading medical devices are trusted worldwide, and the company will expand its portfolio as a leading healthcare provider. Through radiofrequency ablation, Abbott will provide customers with a treatment option that will relieve chronic pain more effectively.
